Arkolith/Insider Trading/RPHM/Form 4

O'Donnell Niall

DirectorReneo Pharmaceuticals, Inc. (RPHM) · full profile →Form 4 · filed Apr 15, 2021
Net Buying
Open-Market Buys
$3.0M
Open-Market Sells
$0
Net Open-Market Flow
$3.0M
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 13, 2021Conversion(C)1.0M——1.0M
Apr 13, 2021Conversion(C)829K——1.9M
Apr 13, 2021Buy(P)200K$15.00$3.0M2.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 13, 2021Conversion(C)4.6M—$00
Apr 13, 2021Conversion(C)3.7M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-21-026826) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML